Full-Time
Business Performance Manager
Regulatory
Updated on 8/12/2026
Amgen
10,001+ employees
Biotech company creating biologic medicines
No salary listed
Hyderabad, Telangana, India
In Person
Bachelor's, Master's, PhD
 Training |
|---|
Get referred to Amgen
See people who can refer or advise you
- A doctorate degree, or a master's degree with 4 to 6 years of related experience, or a bachelor's degree with 6 to 8 years of related experience, or a diploma with 10 to 12 years of related experience.
- Lead the design and delivery of engaging and scalable onboarding and development learning solutions.
- Ensure learning initiatives are inclusive, accessible, and tailored to diverse learner needs.
- Manage the execution of learning activities that align with organizational objectives.
- Support knowledge management methods and procedures that enable the GRAAS organization to capture and share knowledge.
- Support the behavior change necessary for the organization to share and adopt best practices.
- Develop and maintain competency and proficiency models and manage execution of associated learning plans.
- Develop content to support the execution of learning plans.
- Continuously refine onboarding and learning pathways using learner feedback, data insights, and business priorities.
- Measure metrics and key performance indicators to assess the impact of learning initiatives and performance improvement strategies.
- Proven experience supporting the implementation of large-scale learning and performance initiatives.
- Strong knowledge of instructional design, adult learning principles, and performance management practices.
- Proficiency in learning technologies such as learning management systems and eLearning platforms, and in data analysis tools.
- Ability to influence and drive change across all levels of the organization.
- Expertise in assessing and defining how to measure performance.
- Strong written and oral communication skills and attention to detail.
- Strong leadership skills in a team environment, including negotiation, persuasion, collaboration, and analytical judgment.
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Get referred to Amgen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $10.05 billion, and guidance rose to $38.2-$39.4 billion.
- Repatha sales jumped 37% in Q2 2026; Uplizna climbed 90%.
- MariTide Phase 3 programs are enrolling now, with obesity readouts expected in 2027.
What critics are saying
- FDA proposed Tavneos withdrawal on April 27, 2026 after data-integrity findings.
- July 2026 Amgen settled a $74 million IRS-disclosure suit; tax litigation continues.
- July 2026 layoffs hit Amgen again, signaling operating strain and portfolio pruning.
What makes Amgen unique
- Repatha, Uplizna, and Imdelltra diversified Amgen beyond Enbrel and Prolia.
- MariTide’s quarterly-or-sparser dosing targets obesity with lower treatment burden than weekly injectables.
- Amgen’s 2025-2026 launches span cardiology, oncology, and rare disease globally.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.
Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.
Amgen reported second quarter 2026 revenues of $10.1 billion, a 10% increase year-over-year. Product sales grew 9%, driven by volume growth across 22 products that achieved double-digit sales growth. The company's six key growth drivers grew 26% year-over-year, generating nearly 70% of second quarter product sales. GAAP earnings per share increased 65% to $4.37, whilst non-GAAP EPS rose 4% to $6.29. Notable product performance included Repatha sales increasing 37% to $953 million and EVENITY growing 38% to $714 million. The company generated $3.5 billion in free cash flow, compared to $1.9 billion in the prior year period. For full year 2026, Amgen expects total revenues between $38.2 billion and $39.4 billion, with non-GAAP EPS guidance of $22.30 to $23.50.
Amgen secured a preliminary injunction in early June 2026 blocking Colorado's proposed 70% price cap on Enbrel, its rheumatoid arthritis drug. The federal judge's decision preserves pricing flexibility for the legacy asset. However, the company initiated several voluntary Class II recalls of Corlanor and Sensipar batches in the US due to foreign substances and manufacturing deviations. While not yet financially material, the recalls highlight ongoing operational risks. Amgen's investment case depends on its diversified portfolio offsetting pricing pressure and biosimilar competition. The company projects revenue of $40.1 billion and earnings of $9.9 billion by 2029, requiring 2.5% annual revenue growth. Current 2026 guidance stands at $37.1–$38.5 billion in revenue. The combination of pricing relief and quality concerns presents investors with a rebalanced risk-reward profile for the biotech company.
The New England Journal of Medicine has retracted the 2021 clinical trial that supported approval of Amgen's Tavneos, a treatment for ANCA-associated vasculitis that generated $459 million in sales last year. The retraction followed an FDA investigation revealing that results from nine patients were altered after the study database was finalised, whilst some researchers had been unblinded. The FDA alleges the original data showed no statistically significant difference between Tavneos and existing treatments, but subsequent changes made the drug appear more effective. The agency proposed withdrawing Tavneos from the US market in April, whilst European regulators have also recommended removal. Amgen, which acquired ChemoCentryx for $3.7 billion in 2022, continues selling Tavneos and has requested an FDA hearing. The company says it is engaging independent researchers to reanalyse the data.